scholarly journals Oxidative Stress and Matrix Metalloproteinase-9 in Acute Ischemic Stroke

Stroke ◽  
2008 ◽  
Vol 39 (1) ◽  
pp. 100-104 ◽  
Author(s):  
Peter J. Kelly ◽  
Jason D. Morrow ◽  
MingMing Ning ◽  
Walter Koroshetz ◽  
Eng H. Lo ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Acute Ischemic Stroke ◽  
Matrix Metalloproteinase 9 ◽  
Metalloproteinase 9

scholarly journals Association between Increased Matrix Metalloproteinase-9 (MMP-9) Levels with Hyperglycaemia Incidence in Acute Ischemic Stroke Patients

2018 ◽  
Vol 6 (11) ◽  
pp. 2067-2072 ◽  
Author(s):  
Ismail Setyopranoto ◽  
Rusdy Ghazali Malueka ◽  
Andre Stefanus Panggabean ◽  
I Putu Eka Widyadharma ◽  
Ahmad Hamim Sadewa ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Acute Ischemic Stroke ◽  
Matrix Metalloproteinase 9 ◽  
Blood Levels ◽  
Stroke Patients ◽  
Reference Hospital ◽  
The Difference ◽  
Increased Activity ◽  
Metalloproteinase 9

BACKGROUND: Hyperglycemia is common in acute stroke patients. Hyperglycemia can induce the production of reactive oxygen species, causing increased activity of matrix metalloproteinase-9 (MMP-9). AIM: This study aimed to determine an association between the increased levels of MMP-9 and the incidence of hyperglycemia in acute ischemic stroke patients. METHODS: This is a case-control study. Acute ischemic stroke patients admitted to the Stroke Unit of a reference hospital in Yogyakarta, Indonesia was divided into the hyperglycemic and non-hyperglycemic group. Demographic and clinical characteristics of each subject were recorded, and blood levels of MMP-9 were measured. Seventy-one patients were recruited, 40 subjects in the hyperglycemic group and 31 subjects in the non-hyperglycemic group. RESULTS: The median levels of blood MMP-9 level in the hyperglycemic and non-hyperglycemic group were 974.37 and 748.48 ng/mL, respectively, and the difference was statistically not significant (95% CI, 191.24-2849.53; p = 0.07). When the calculated cut-off point of 600.99 ng/mL was used, the proportion of patients with higher MMP-9 levels was significantly more in the hyperglycemic group compared with the ones in the non-hyperglycemic group (82.5% and 54.8%, respectively; OR = 3.88; p = 0.011). CONCLUSION: We concluded that the proportion of patients with MMP-9 level >600.99 ng/mL was significantly higher in acute ischemic stroke patients with hyperglycemia.ng/mL was significantly higher in acute ischemic stroke patients with hyperglycemia.

scholarly journals The Alteration of Plasma Matrix Metalloproteinase-9 Level after the Addition of Bromelin 500 mg to Standard Therapy of Acute Ischemic Stroke and Its Correlation with Outcome

2018 ◽  
Vol 6 (4) ◽  
pp. 624-628
Author(s):  
Puji Pinta Sinurat ◽  
Hasan Sjahrir ◽  
Aldy S. Rambe ◽  
Ratna Akbari Ganie
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Acute Ischemic Stroke ◽  
Standard Therapy ◽  
Statistical Correlation ◽  
Matrix Metalloproteinase 9 ◽  
Standard Group ◽  
Double Blind Study ◽  
Double Blind ◽  
Metalloproteinase 9

BACKGROUND: Matrix metalloproteinase-9 (MMP9) expression due to ischemic cause spreading of brain damage. Previous studies have reported that Bromelin was beneficial as anti-inflammation and prevent brain tissue damage.AIM: This study aimed to determine the alteration of plasma MMP9 level after addition of Bromelin 500 mg to Standard therapy and its correlation with outcome in acute ischemic stroke.METHODS: This was a preliminary report of a prospective randomised, double-blind study with pre and post-test design, forty-six acute ischemic stroke patients were randomly allocated with Bromelin and Standard groups. Measurement of MMP9 and outcome were performed before and after 14-days treatment.RESULT: The Bromelin group showed a significant decrement of MMP9 level, from 6.02 ± 0.32 ng/ml before treatment to 5.50 ± 0.94 ng/ml after treatment (p = 0.028). There was a negative correlation between MMP9 level and mRS (r= -0.03; p = 0.905) and a positive correlation toward BI (r = 0.039; p = 0.859), while the Standard group showed increased MMP9 level from 5.82 ± 0.71 ng/ml to 5.91 ± 0.83 ng/ml (p = 0.616) which was correlated insignificantly to outcome.CONCLUSION: We concluded that the addition of 500 mg Bromelin to standard ischemic stroke therapy reduced MMP9 level significantly and correlated to outcome improvement. However, there is a tight statistical correlation.

Matrix metalloproteinase-9 contributes to the increase of tau protein in serum during acute ischemic stroke

2010 ◽  
Vol 17 (8) ◽  
pp. 997-999 ◽  
Author(s):  
Jacek Kurzepa ◽  
Joanna Bielewicz ◽  
Aneta Grabarska ◽  
Zbigniew Stelmasiak ◽  
Marta Stryjecka-Zimmer ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Acute Ischemic Stroke ◽  
Tau Protein ◽  
Matrix Metalloproteinase 9 ◽  
Metalloproteinase 9

Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke

2017 ◽  
Vol 26 (4) ◽  
pp. 733-740 ◽  
Author(s):  
Maged M. Abdelnaseer ◽  
Nervana M. Elfauomy ◽  
Eman H. Esmail ◽  
Manal M. Kamal ◽  
Enji H. Elsawy
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Acute Ischemic Stroke ◽  
Matrix Metalloproteinase 9 ◽  
Metalloproteinase 9
Sign in / Sign up

Export Citation Format

Share Document